Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer
Non–small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers. In recent years, treatment with immune checkpoint inhibitors (ICIs) has gradually improved the survival rate of patients with NSCLC, especially those in the advanced stages. ICIs can block the tolerance pathways that are ove...
| Main Authors: | , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Frontiers Media S.A.
2024-02-01
|
| 丛编: | Frontiers in Immunology |
| 主题: | |
| 在线阅读: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1343450/full |